Michael LaCascia joined Foghorn Therapeutics in November 2020 as chief legal officer. He brings over 30 years of legal experience with broad corporate, securities, governance, and transactional expertise in the biotechnology industry.
Before joining Foghorn, Mike was the chief legal officer at Q-State Biosciences. As part of the executive leadership team, he worked to transition Q-State’s corporate strategy from providing enabling discovery services to the discovering of its proprietary therapeutics. Prior to that, Mike was the senior vice president, general counsel and secretary of Vertex Pharmaceuticals, where he led its global legal function, supported numerous business development initiatives, and enhanced corporate governance for the company as it witnessed substantial growth during several product approvals. Mike also served as an attorney for more than two decades at WilmerHale LLP (and its constituent firm, Hale and Dorr) where he was a partner in that firm’s corporate practice specializing in securities, mergers and acquisitions (M&A) and corporate governance matters.
In addition, Mike was an adjunct faculty instructor at Boston University School of Law for over a decade teaching Negotiated M&A to U.S. and international law students.
Mike received his Juris Doctor degree from Boston University and his Bachelor of Arts in economics from Harvard College.